12 Information Technology Stocks Moving In Thursday’s After-Market Session

Gainers Applied Mat (NASDAQ:AMAT) shares rose 11.7% to $209.64 during Thursday’s after-market session. The market value of their…

Gainers

  • Applied Mat (NASDAQ:AMAT) shares rose 11.7% to $209.64 during Thursday’s after-market session. The market value of their outstanding shares is at $174.4 billion. As per the news, the Q1 earnings report came out today.
  • Procore Technologies (NYSE:PCOR) shares moved upwards by 8.54% to $80.96. The market value of their outstanding shares is at $11.6 billion. As per the press release, Q4 earnings came out today.
  • Iveda Solutions (NASDAQ:IVDA) stock rose 5.78% to $0.88. The company’s market cap stands at $14.1 million.
  • Backblaze (NASDAQ:BLZE) shares moved upwards by 5.52% to $8.6. The company’s market cap stands at $323.3 million. The company’s, Q4 earnings came out today.
  • Quantum (NASDAQ:QMCO) shares increased by 4.97% to $0.51. The company’s market cap stands at $48.8 million.
  • Argo Blockchain (NASDAQ:ARBK) shares rose 4.65% to $2.7. The market value of their outstanding shares is at $155.8 million.

Losers

  • Auddia (NASDAQ:AUUD) shares decreased by 21.4% to $0.18 during Thursday’s after-market session. The company’s market cap stands at $3.5 million.
  • ARB IOT Group (NASDAQ:ARBB) shares decreased by 6.9% to $2.16. The market value of their outstanding shares is at $57.1 million.
  • UTime (NASDAQ:WTO) shares fell 6.82% to $0.26. The company’s market cap stands at $3.5 million.
  • X3 Holdings (NASDAQ:XTKG) stock fell 5.73% to $0.76. The market value of their outstanding shares is at $4.0 million.
  • MultiSensor AI Holdings (NASDAQ:MSAI) shares declined by 5.51% to $3.4. The company’s market cap stands at $40.6 million.
  • Infobird Co (NASDAQ:IFBD) shares fell 5.45% to $1.39. The company’s market cap stands at $14.8 million.
    See Also: www.benzinga.com/money/tech-stocks/

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Newly Listed Lenz Therapeutics’ Vision Loss Experimental Drug Meets Primary Goal In Late-Stage Study

LENZ Therapeutics unveils Phase 3 CLARITY study results on aceclidine formulations, LNZ100 & LNZ101. LNZ100 demonstrates significant improvement in Presbyopia, achieving primary and key secondary endpoints without compromising distance visual acuity. LNZ100's safety profile remains favorable, paving the way for its lead candidacy, poised for mid-2024 NDA submission.

LENZ